UBS Reiterates Buy Rating on ResMed (RMD) Following GLP-1 Survey
Tweet Send to a Friend
UBS analyst Marcus Curley reiterated a Buy rating and $325.00 price target on ResMed (NYSE: RMD).The analyst commented, "Industry feedback ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
